The potential impact of structural genomics on tuberculosis drug discovery
- 31 January 2006
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 11 (1-2), 28-34
- https://doi.org/10.1016/s1359-6446(05)03667-6
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Does DOTS work in populations with drug-resistant tuberculosis?The Lancet, 2005
- How Soon after Infection with HIV Does the Risk of Tuberculosis Start to Increase? A Retrospective Cohort Study in South African Gold MinersThe Journal of Infectious Diseases, 2005
- Worldwide Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2002
- Global Burden of TuberculosisJAMA, 1999
- Tuberculosis in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1999
- ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus ProteaseAntimicrobial Agents and Chemotherapy, 1998
- Structure−Activity Relationship Studies of Novel Carbocyclic Influenza Neuraminidase InhibitorsJournal of Medicinal Chemistry, 1998
- Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 ProteaseJournal of Medicinal Chemistry, 1997
- Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzymeJournal of the American Chemical Society, 1995
- Rational design of potent sialidase-based inhibitors of influenza virus replicationNature, 1993